August 25, 2026
XPeng posted a wider loss and missed sales estimates, adding pressure to EV and biotech names.
What happened
XPeng reported a wider adjusted loss and sales that fell short of Wall Street estimates. The stock moved 2.6 percent, a larger move than half of its daily swings over three years. Biotechs Spruce Biosciences and BioCardia also traded on regulatory updates, but the moves were small relative to their own histories.
Why it matters
The XPeng miss signals that Chinese electric vehicle companies are still burning cash while revenue underwhelms, at a time when global competition is intensifying. That pain can ripple to suppliers and peers that trade on similar growth narratives. The small biotech reactions underscore that early stage FDA progress alone is not enough to lift valuations when the broader market is sorting winners from losers.
The case against
A single quarterly miss does not break the long term electrification trend. XPeng deliveries could recover quickly, and the factory automation buildout we track suggests the underlying manufacturing shift remains intact.
What settles it
Next quarter delivery numbers from XPeng and peer Li Auto.